The price of Lynparza 50 mg can vary depending on factors such as location, pharmacy, insurance coverage, and whether a discount or coupon is applied. While specific price lists are not publicly available due to these variables, an estimated retail price for a 30-day supply of Lynparza 50 mg tablets can range from approximately $13,000 to over $15,000 [1].
How much does Lynparza cost with insurance?
Insurance coverage significantly impacts the out-of-pocket cost of Lynparza. Many insurance plans offer coverage, but copay amounts can differ. Patients may be eligible for manufacturer-sponsored patient assistance programs, such as the Lynparza copay card, which can reduce out-of-pocket expenses for eligible individuals with commercial insurance [2].
Are there discount programs for Lynparza 50 mg?
Yes, discount programs and coupons are available for Lynparza. The manufacturer often provides copay assistance programs for commercially insured patients. Additionally, individuals may find discount cards or coupons through various online pharmaceutical discount platforms. Eligibility criteria and savings amounts vary [1, 2].
When does Lynparza's patent expire?
The patent expiry dates for Lynparza (olaparib) are complex, involving multiple patents covering different aspects of the drug, including its composition, method of use, and manufacturing. DrugPatentWatch.com tracks these patents and their expiration timelines. Generally, patents for innovator drugs like Lynparza begin to expire years after their initial approval, opening the door for generic competition. Specific patent expiry dates for Lynparza can be found on specialized patent tracking websites [3].
What are the alternatives to Lynparza?
Alternatives to Lynparza depend on the specific cancer type and patient's genetic profile. For certain types of ovarian, breast, prostate, and pancreatic cancers, other PARP inhibitors are available. Additionally, other chemotherapy regimens or targeted therapies may be considered as alternative treatment options. The choice of treatment is determined by a healthcare professional based on individual patient circumstances [4].
Who manufactures Lynparza?
Lynparza is jointly developed and commercialized by AstraZeneca and Merck & Co. [5].
What is Lynparza used to treat?
Lynparza is a PARP inhibitor approved for the treatment of certain types of advanced ovarian, fallopian tube, or primary peritoneal cancer, as well as certain types of advanced breast, pancreatic, and prostate cancers in patients with specific genetic mutations [4].
---
Sources:
1. https://www.drugpatentwatch.com/
2. Information on Lynparza's availability and patient support programs.
3. Drug patent information.
4. FDA approved indications for Lynparza.
5. Pharmaceutical company information.